A Perspective on Nanoparticle Universal Influenza Vaccines

被引:35
|
作者
Deng, Lei [1 ]
Wang, Bao-Zhong [1 ]
机构
[1] Georgia State Univ, Ctr Inflammat Immun & Infect, 145 Piedmont Ave SE, Atlanta, GA 30302 USA
来源
ACS INFECTIOUS DISEASES | 2018年 / 4卷 / 12期
基金
美国国家卫生研究院;
关键词
prophylaxis; virus-like particle; self-assembling; long-lasting; headless hemagglutinin; matrix protein 2; VIRUS-LIKE PARTICLES; IMPROVED CROSS-PROTECTION; GOLD NANOPARTICLES; IMMUNE-RESPONSES; HEMAGGLUTININ TRIMERS; EXTRACELLULAR DOMAIN; ALVEOLAR MACROPHAGES; MONOCLONAL-ANTIBODY; PANDEMIC INFLUENZA; MATRIX PROTEIN-2;
D O I
10.1021/acsinfecdis.8b00206
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Annually recurring seasonal influenza causes massive economic loss and poses severe threats to public health worldwide. The current seasonal influenza vaccines are the most effective means of preventing influenza infections but possess major weaknesses. Seasonal influenza vaccines require annual updating of the vaccine strains. However, it is an unreachable task to accurately predict the future circulating strains. Vaccines with mismatched strains dramatically compromise the vaccine efficacy. In addition, the seasonal influenza vaccines are ineffective against an unpredictable pandemic. A universal influenza vaccine would overcome these weaknesses of the seasonal vaccines and abolish the threat of influenza pandemics. One approach under investigation is to design influenza vaccine immunogens based on conserved, type-specific amino acid sequences and conformational epitopes, rather than strain-specific. Such vaccines can elicit broadly reactive humoral and cellular immunity. Universal influenza vaccine development has intensively employed nanotechnology because the structural and morphological properties of nanoparticles dramatically improve vaccine immunogenicity and the induced immunity duration. Layered protein nanoparticles can decrease off-target immune responses, fine-tune antigen recognition and processing, and facilitate comprehensive immune response induction. Herein, we review the designs of effective nanoparticle universal influenza vaccines, the recent discoveries of specific nanoparticle features that contribute to immunogenicity enhancement, and recent progress in clinical trials.
引用
收藏
页码:1656 / 1665
页数:19
相关论文
共 50 条
  • [31] Workshop report: Immunoassay standardisation for "universal" influenza vaccines
    Pavlova, Sophia
    D'Alessio, Flavia
    Houard, Sophie
    Remarque, Edmond J.
    Stockhofe, Norbert
    Engelhardt, Othmar G.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2017, 11 (03) : 194 - 201
  • [32] Universal influenza vaccines, science fiction or soon reality?
    de Vries, Rory D.
    Altenburg, Arwen F.
    Rimmelzwaan, Guus F.
    EXPERT REVIEW OF VACCINES, 2015, 14 (10) : 1299 - 1301
  • [33] Universal influenza virus vaccines: need for clinical trials
    Krammer, Florian
    Palese, Peter
    NATURE IMMUNOLOGY, 2014, 15 (01) : 3 - 5
  • [34] Virus-like particles as universal influenza vaccines
    Kang, Sang-Moo
    Kim, Min-Chul
    Compans, Richard W.
    EXPERT REVIEW OF VACCINES, 2012, 11 (08) : 995 - 1007
  • [35] The Next Generation of Influenza Vaccines: Towards a Universal Solution
    McMillan, Christopher L. D.
    Young, Paul R.
    Watterson, Daniel
    Chappell, Keith J.
    VACCINES, 2021, 9 (01) : 1 - 20
  • [36] Future epidemiological and economic impacts of universal influenza vaccines
    Sah, Pratha
    Alfaro-Murillo, Jorge A.
    Fitzpatrick, Meagan C.
    Neuzil, Kathleen M.
    Meyers, Lauren A.
    Singer, Burton H.
    Galvani, Alison P.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (41) : 20786 - 20792
  • [37] Quadrivalent influenza nanoparticle vaccines induce broad protection
    Seyhan Boyoglu-Barnum
    Daniel Ellis
    Rebecca A. Gillespie
    Geoffrey B. Hutchinson
    Young-Jun Park
    Syed M. Moin
    Oliver J. Acton
    Rashmi Ravichandran
    Mike Murphy
    Deleah Pettie
    Nick Matheson
    Lauren Carter
    Adrian Creanga
    Michael J. Watson
    Sally Kephart
    Sila Ataca
    John R. Vaile
    George Ueda
    Michelle C. Crank
    Lance Stewart
    Kelly K. Lee
    Miklos Guttman
    David Baker
    John R. Mascola
    David Veesler
    Barney S. Graham
    Neil P. King
    Masaru Kanekiyo
    Nature, 2021, 592 : 623 - 628
  • [38] Progress on adenovirus-vectored universal influenza vaccines
    Kui Xiang
    Guan Ying
    Zhou Yan
    Yan Shanshan
    Zhang Lei
    Li Hongjun
    Sun Maosheng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (05) : 1209 - 1222
  • [39] Universal influenza virus vaccines: need for clinical trials
    Florian Krammer
    Peter Palese
    Nature Immunology, 2014, 15 : 3 - 5
  • [40] Quadrivalent influenza nanoparticle vaccines induce broad protection
    Boyoglu-Barnum, Seyhan
    Ellis, Daniel
    Gillespie, Rebecca A.
    Hutchinson, Geoffrey B.
    Park, Young-Jun
    Moin, Syed M.
    Acton, Oliver J.
    Ravichandran, Rashmi
    Murphy, Mike
    Pettie, Deleah
    Matheson, Nick
    Carter, Lauren
    Creanga, Adrian
    Watson, Michael J.
    Kephart, Sally
    Ataca, Sila
    Vaile, John R.
    Ueda, George
    Crank, Michelle C.
    Stewart, Lance
    Lee, Kelly K.
    Guttman, Miklos
    Baker, David
    Mascola, John R.
    Veesler, David
    Graham, Barney S.
    King, Neil P.
    Kanekiyo, Masaru
    NATURE, 2021, 592 (7855) : 623 - +